cabergoline, Dostinex (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
DOSING: Cabergoline is better tolerated when administered with food.
For the treatment of hyperprolactinemia in adults: The recommended starting dose of cabergoline is 0.25 mg twice weekly. The dose is gradually increased usually by adding 0.25 mg per week at monthly intervals up to 1 mg twice weekly based on serum prolactin levels. Once a normal serum prolactin level is maintained for at least 6 months, cabergoline may be discontinued. Prolactin levels in these patients must be monitored to determine if restarting treatment is necessary.
DRUG INTERACTIONS: Cabergoline is related to the ergot alkaloids. The use of cabergoline with other ergot alkaloids is not recommended due to the increased risk for adverse events. Ergot alkaloids are commonly used to treat migraine headaches. Therefore, patients receiving treatment for migraine headaches should discuss treatment with cabergoline with their doctor or pharmacist before using cabergoline.
Cabergoline works by stimulating dopamine receptors in the brain. It should not be used with dopamine antagonists or blockers which might decrease or cancel out the beneficial effects of cabergoline. Examples of dopamine antagonists are phenothiazines, butyrophenones, thioxanthenes, and metoclopramide (Reglan).
PREGNANCY: No adequate or well-controlled studies have been conducted in pregnant women. Due to the lack of conclusive safety data, cabergoline should only be used in pregnancy if clearly needed. Cabergoline is classified in FDA pregnancy risk category B.
NURSING MOTHERS: Cabergoline should not be used in breastfeeding mothers because it interferes with the production of breast milk. It is not known whether cabergoline is excreted in human milk.
REFERENCE: FDA Prescribing Information.
Medically Reviewed by a Doctor on 12/10/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index